NZ590073A - Macrocyclic indole derivatives useful as hepatitis c virus inhibitors - Google Patents

Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Info

Publication number
NZ590073A
NZ590073A NZ590073A NZ59007309A NZ590073A NZ 590073 A NZ590073 A NZ 590073A NZ 590073 A NZ590073 A NZ 590073A NZ 59007309 A NZ59007309 A NZ 59007309A NZ 590073 A NZ590073 A NZ 590073A
Authority
NZ
New Zealand
Prior art keywords
hepatitis
indole derivatives
derivatives useful
virus inhibitors
macrocyclic indole
Prior art date
Application number
NZ590073A
Other languages
English (en)
Inventor
Sandrine Marie Helene Vendeville
Pierre Jean-Marie Bernard Raboisson
Tse-I Lin
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Priority to NZ603343A priority Critical patent/NZ603343A/xx
Publication of NZ590073A publication Critical patent/NZ590073A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ590073A 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors NZ590073A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ603343A NZ603343A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04
PCT/EP2009/004942 WO2010003658A1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
NZ590073A true NZ590073A (en) 2012-11-30

Family

ID=40972916

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ603343A NZ603343A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
NZ590073A NZ590073A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ603343A NZ603343A (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

Country Status (31)

Country Link
US (2) US8921355B2 (https=)
EP (1) EP2310396B1 (https=)
JP (2) JP5426671B2 (https=)
KR (1) KR101640374B1 (https=)
CN (1) CN102089314B (https=)
AP (1) AP2743A (https=)
AR (1) AR072726A1 (https=)
AU (1) AU2009267389B8 (https=)
BR (1) BRPI0915887B8 (https=)
CA (1) CA2729307C (https=)
CL (1) CL2011000032A1 (https=)
CO (1) CO6351793A2 (https=)
CR (1) CR20110076A (https=)
DK (1) DK2310396T3 (https=)
EA (1) EA019008B1 (https=)
EC (1) ECSP11010750A (https=)
ES (1) ES2651038T3 (https=)
HN (1) HN2011000072A (https=)
HR (1) HRP20171892T1 (https=)
HU (1) HUE035244T2 (https=)
IL (1) IL210086A (https=)
LT (1) LT2310396T (https=)
MX (1) MX2011000276A (https=)
NI (1) NI201100010A (https=)
NO (1) NO2310396T3 (https=)
NZ (2) NZ603343A (https=)
SI (1) SI2310396T1 (https=)
SV (1) SV2011003796A (https=)
TW (1) TWI454476B (https=)
UY (1) UY31973A (https=)
WO (1) WO2010003658A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
CA2796243A1 (en) 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) * 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
ES2655942T3 (es) 2011-09-02 2018-02-22 Novartis Ag Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
EP2890378A2 (en) 2012-08-31 2015-07-08 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
EP0966465B1 (en) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AP1498A (en) * 1999-03-19 2005-11-21 Vertex Pharma Inhibitors of impdh enzyme.
US6891331B2 (en) 2000-08-30 2005-05-10 Matsushita Electric Industrial Co., Ltd. Plasma display unit and production method thereof
JP4902361B2 (ja) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200800225A (en) 2005-09-02 2008-01-01 Tibotec Pharm Ltd Benzodiazepines as HCV inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
AU2008277440A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
PT2401272T (pt) 2009-02-27 2017-02-28 Janssen Pharmaceuticals Inc Sal amorfo de um inibidor macrocíclico de hcv
CA2796243A1 (en) 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
EP2890378A2 (en) 2012-08-31 2015-07-08 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
AR072726A1 (es) 2010-09-15
SI2310396T1 (en) 2018-01-31
BRPI0915887B8 (pt) 2021-05-25
NI201100010A (es) 2011-09-07
US20140107101A1 (en) 2014-04-17
KR20110040889A (ko) 2011-04-20
CR20110076A (es) 2011-11-10
CN102089314B (zh) 2014-07-23
AP2010005521A0 (en) 2010-12-31
CL2011000032A1 (es) 2011-07-15
AU2009267389A1 (en) 2010-01-14
CA2729307C (en) 2017-08-29
MX2011000276A (es) 2011-03-02
EP2310396A1 (en) 2011-04-20
IL210086A0 (en) 2011-02-28
JP5808370B2 (ja) 2015-11-10
BRPI0915887B1 (pt) 2020-02-18
JP2011527299A (ja) 2011-10-27
AU2009267389B8 (en) 2013-07-04
ECSP11010750A (es) 2011-08-31
NO2310396T3 (https=) 2018-02-03
UY31973A (es) 2010-01-29
LT2310396T (lt) 2017-12-27
DK2310396T3 (en) 2017-12-11
US8921355B2 (en) 2014-12-30
HRP20171892T1 (hr) 2018-01-12
EA019008B1 (ru) 2013-12-30
AP2743A (en) 2013-09-30
WO2010003658A1 (en) 2010-01-14
CN102089314A (zh) 2011-06-08
CO6351793A2 (es) 2011-12-20
TWI454476B (zh) 2014-10-01
ES2651038T3 (es) 2018-01-23
HK1155734A1 (en) 2012-05-25
HN2011000072A (es) 2013-09-01
TW201014865A (en) 2010-04-16
BRPI0915887A2 (pt) 2015-11-03
US20110105473A1 (en) 2011-05-05
JP5426671B2 (ja) 2014-02-26
CA2729307A1 (en) 2010-01-14
US9427440B2 (en) 2016-08-30
HUE035244T2 (hu) 2018-05-02
SV2011003796A (es) 2011-04-08
NZ603343A (en) 2013-08-30
IL210086A (en) 2014-05-28
JP2014028818A (ja) 2014-02-13
KR101640374B1 (ko) 2016-07-18
EP2310396B1 (en) 2017-09-06
AU2009267389A8 (en) 2013-07-04
AU2009267389B2 (en) 2013-05-30
EA201170153A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
NZ590073A (en) Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
MX2009012595A (es) Derivados de espiroindolinona.
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
MX2009014208A (es) Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
MX2009009290A (es) Compuestos activos en ppar.
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
PH12013500363A1 (en) Use of substituted quinazoline compounds in treating age-related macular degeneration
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MY150542A (en) Cmet inhibitors
TW200716636A (en) Heterocyclic spiro-compounds
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
SG178953A1 (en) Heterocylcic derivatives as inhibitors of glutaminyl cyclase
TNSN07252A1 (en) Indole derivatives for treating viral infections
MY148609A (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
IN2012DN01855A (https=)
MX2010009268A (es) Compuestos que son inhibidores de erk.
NZ579928A (en) Fluorinated derivatives of deferiprone
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
NZ594508A (en) [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
SG196785A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives
IL200469A0 (en) Benzimidazole derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2016 BY CPA GLOBAL

Effective date: 20130531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUL 2019 BY CPA GLOBAL

Effective date: 20140903

ASS Change of ownership

Owner name: JANSSEN SCIENCES IRELAND UC, IE

Effective date: 20150723

LAPS Patent lapsed